Business Context and Reporting Period
This Form 8-K filing by Histogenics Corporation (trading under the symbol HSGX) is dated June 23, 2017. The report addresses a change in the listing status of the Company's common stock on The NASDAQ Stock Market LLC.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin data. However, it references a material financial condition from the prior quarter:
- Stockholders' Equity: Fell below $10 million as reported in the Form 10-Q for the period ended March 31, 2017.
No other debt, liquidity, or operational metrics are disclosed in this specific document.
Material Changes
The primary material change reported is the transfer of the Company's listing:
- Listing Transfer: The Company's application to transfer its common stock from the NASDAQ Global Market to the NASDAQ Capital Market was approved.
- Effective Date: The transfer occurred at the opening of business on June 30, 2017.
- Reason for Transfer: The Company failed to meet the continued listing requirements of the NASDAQ Global Market (Rule 5450(b)(1)(A)) due to stockholders' equity falling below the $10 million threshold.
- Trading Impact: The Company stated that this move will not affect the trading of its common stock, which will continue under the symbol "HSGX."
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the listing transfer. The Company noted that the NASDAQ Capital Market operates in substantially the same manner as the Global Market but has less stringent listing requirements.
Investor Verification Checklist
- Verify the Company's current stockholders' equity status to ensure continued compliance with NASDAQ Capital Market requirements.
- Review the Form 10-Q for the period ended March 31, 2017, to understand the financial drivers behind the equity decline.
- Confirm that the stock continues to trade under the symbol "HSGX" on the NASDAQ Capital Market.
- Check for any subsequent filings regarding capital raises or financial restructuring intended to address the equity shortfall.